Legacy Wealth Asset Management LLC Has $2.76 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Legacy Wealth Asset Management LLC lifted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 31.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 185,472 shares of the company's stock after acquiring an additional 44,635 shares during the period. Takeda Pharmaceutical comprises approximately 0.8% of Legacy Wealth Asset Management LLC's holdings, making the stock its 17th largest position. Legacy Wealth Asset Management LLC's holdings in Takeda Pharmaceutical were worth $2,758,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in TAK. QRG Capital Management Inc. boosted its holdings in shares of Takeda Pharmaceutical by 16.8% during the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock worth $4,364,000 after purchasing an additional 47,490 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Takeda Pharmaceutical by 48.6% during the 4th quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock valued at $600,000 after buying an additional 14,831 shares during the period. US Bancorp DE grew its holdings in shares of Takeda Pharmaceutical by 21.2% during the 4th quarter. US Bancorp DE now owns 124,332 shares of the company's stock valued at $1,646,000 after acquiring an additional 21,744 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Takeda Pharmaceutical by 27.0% in the fourth quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock worth $205,000 after acquiring an additional 3,071 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Takeda Pharmaceutical by 60.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock worth $2,409,000 after acquiring an additional 68,200 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Down 0.7%

Shares of NYSE TAK traded down $0.11 during trading hours on Tuesday, hitting $14.97. The stock had a trading volume of 1,105,752 shares, compared to its average volume of 1,935,681. The firm's 50-day moving average price is $14.66 and its two-hundred day moving average price is $14.06. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.43. The company has a market capitalization of $47.63 billion, a P/E ratio of 37.43, a P/E/G ratio of 0.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). The business had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.